BMRA · Biomerica Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $987.0K | $1.21M | $1.38M | $1.64M | $1.12M | $1.81M | $1.57M | $1.02M | $1.71M | $1.48M |
| Cost of Revenue | $1.03M | $1.16M | $956.0K | $1.20M | $1.10M | $1.52M | $1.24M | $1.17M | $1.30M | $1.13M |
| Gross Profit | ($44.0K) | $51.0K | $424.0K | $437.0K | $19.0K | $289.0K | $325.0K | ($149.0K) | $412.0K | $351.9K |
| R&D | $178.0K | $193.0K | $212.0K | $257.0K | $217.0K | $297.0K | $412.0K | $343.0K | $472.0K | $461.9K |
| SG&A | $1.08M | $1.23M | $1.33M | $1.17M | $1.01M | $1.36M | $1.52M | $1.51M | $1.17M | $1.56M |
| Total Operating Expenses | $1.25M | $1.42M | $1.54M | $1.43M | $1.23M | $1.66M | $1.93M | $1.85M | $1.64M | $2.02M |
| D&A | - | - | $20.0K | - | - | $21.0K | - | - | $21.0K | $16.0K |
| Operating Income | ($1.30M) | ($1.37M) | ($1.12M) | ($993.0K) | ($1.21M) | ($1.37M) | ($1.61M) | ($2.00M) | ($1.23M) | ($1.67M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $8.0K | $5.0K | $3.0K | ($3.0K) | ($4.0K) | $4.0K | $8.0K | $4.0K | $23.0K | $1.3K |
| Net Income | ($1.31M) | ($1.32M) | $2.0K | ($950.0K) | ($1.16M) | ($1.32M) | ($1.51M) | ($1.92M) | ($1.13M) | ($1.63M) |
| EPS - Basic | ($0.44) | ($0.45) | $0.00 | ($0.06) | ($0.48) | ($0.64) | ($0.72) | ($0.88) | ($0.56) | ($0.96) |
| EPS - Diluted | ($0.44) | ($0.45) | $0.00 | ($0.06) | ($0.48) | ($0.64) | ($0.72) | ($0.88) | ($0.56) | ($0.96) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.40M | $2.54M | $3.05M | $2.40M | $3.06M | $2.82M | $4.17M | $5.32M | $7.99M | $9.72M |
| Accounts Receivable | $941.0K | $947.0K | $1.21M | $731.0K | $1.27M | $1.55M | $947.0K | $1.13M | $1.43M | $722.0K |
| Inventory | $1.49M | $1.52M | $1.47M | $1.49M | $1.66M | $1.94M | $2.38M | $2.13M | $1.88M | $2.06M |
| Accounts Payable | - | - | - | $295.0K | - | - | $288.0K | - | - | $344.0K |
| Current Assets | $4.12M | $5.19M | $5.90M | $4.88M | $6.20M | $6.45M | $7.73M | $8.85M | $11.57M | $12.80M |
| Total Assets | $5.95M | $6.03M | $6.85M | $5.95M | $7.38M | $7.87M | $9.25M | $10.34M | $13.22M | $14.45M |
| Current Liabilities | $1.74M | $1.60M | $1.69M | $1.74M | $1.65M | $2.15M | $2.20M | $1.99M | $1.75M | $1.95M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.84M | $1.60M | $1.70M | $1.84M | $1.84M | $2.52M | $2.66M | $2.53M | $2.45M | $2.73M |
| Stockholders' Equity | $3.32M | $4.43M | $5.16M | $4.11M | $5.53M | $5.35M | $6.59M | $7.81M | $10.77M | $11.72M |
| Retained Earnings | ($53.17M) | ($54.49M) | ($53.17M) | ($53.17M) | ($51.62M) | ($49.51M) | ($48.20M) | ($46.77M) | ($43.35M) | ($42.22M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($268.0K) | - | - | ($1.34M) | - | - | ($1.67M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($63.0K) | - |
| Financing Cash Flow | - | - | $920.0K | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | $21.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($1.70M) | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -4.5% | 4.2% | 30.7% | 26.7% | 1.7% | 16.0% | 20.7% | -14.7% | 24.1% | 23.7% |
| Operating margin | -131.5% | -113.5% | -81.0% | -60.7% | -108.1% | -75.7% | -102.6% | -196.7% | -71.9% | -112.4% |
| EBITDA margin | - | - | -79.6% | - | - | -74.5% | - | - | -70.7% | -111.3% |
| Net margin | -132.9% | -109.1% | 0.1% | -58.1% | -103.9% | -72.8% | -96.2% | -188.6% | -66.1% | -109.7% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -98.9% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.50 | - |
| R&D / Revenue | 18.0% | 16.0% | 15.4% | 15.7% | 19.4% | 16.4% | 26.3% | 33.7% | 27.6% | 31.2% |
| SG&A / Revenue | 109.0% | 101.7% | 96.4% | 71.7% | 90.4% | 75.3% | 97.1% | 148.3% | 68.4% | 105.0% |
| Effective tax rate | - | - | 60.0% | - | - | - | - | - | - | - |
| Return on assets | -22.1% | -21.9% | 0.0% | -16.0% | -15.8% | -16.7% | -16.3% | -18.5% | -8.6% | -11.3% |
| Return on equity | -39.6% | -29.8% | 0.0% | -23.1% | -21.0% | -24.6% | -22.9% | -24.6% | -10.5% | -13.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.37 | 3.25 | 3.48 | 2.80 | 3.76 | 3.00 | 3.51 | 4.44 | 6.63 | 6.58 |
| Quick ratio | 1.51 | 2.29 | 2.61 | 1.95 | 2.76 | 2.09 | 2.43 | 3.37 | 5.55 | 5.52 |
| Cash ratio | 1.38 | 1.59 | 1.80 | 1.38 | 1.85 | 1.31 | 1.89 | 2.67 | 4.58 | 5.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.79 | 1.36 | 1.33 | 1.45 | 1.33 | 1.47 | 1.40 | 1.32 | 1.23 | 1.23 |
| Liabilities / Assets | 0.31 | 0.26 | 0.25 | 0.31 | 0.25 | 0.32 | 0.29 | 0.25 | 0.19 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | 0.20 | 0.20 | 0.28 | 0.15 | 0.23 | 0.17 | 0.10 | 0.13 | 0.10 |
| Inventory turnover | 0.69 | 0.76 | 0.65 | 0.80 | 0.66 | 0.78 | 0.52 | 0.55 | 0.69 | 0.55 |
| Days sales outstanding | 348d | 286d | 319d | 163d | 414d | 313d | 221d | 406d | 305d | 178d |
| Days inventory outstanding | 527d | 480d | 562d | 454d | 549d | 467d | 698d | 666d | 527d | 664d |
| Days payable outstanding | - | - | - | 90d | - | - | 85d | - | - | 111d |
| Cash conversion cycle | - | - | - | 527d | - | - | 834d | - | - | 731d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.9x | 1.6x | 1.6x | 12.7x | 20.2x | 11.1x | 11.8x | 21.0x | 16.0x | 12.6x |
| P / S | 6.3x | 5.7x | 6.0x | 31.9x | 100.1x | 32.8x | 49.8x | 161.4x | 100.6x | 99.5x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -11.8% | -26.0% | -23.6% | 4.4% | 10.0% | 5.5% | 5.7% | -8.5% | 4.6% | -68.1% |
| Revenue CAGR (3y) | -3.9% | -6.5% | -5.5% | -29.4% | -47.3% | 12.7% | 4.5% | -34.6% | 12.8% | -2.4% |
| Revenue CAGR (5y) | -22.9% | -2.5% | 2.9% | 0.5% | -1.0% | 8.6% | 0.9% | -4.2% | 6.1% | -1.7% |
| Gross profit growth (YoY) | - | -88.3% | 46.7% | 34.5% | - | -29.9% | -7.6% | - | - | -54.4% |
| Operating income growth (YoY) | -7.3% | -38.3% | 18.3% | 38.2% | 39.5% | -11.0% | 3.5% | -21.1% | 40.5% | -47.5% |
| Net income growth (YoY) | -12.8% | -38.9% | - | 37.0% | 39.4% | -16.3% | 7.3% | -16.3% | 45.4% | -44.5% |
| EPS growth (YoY) | 8.3% | -650.0% | - | 91.7% | 45.5% | -14.3% | 25.0% | -633.3% | -250.0% | -966.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -5.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -40.1% | 8.0% | -3.6% | -37.7% | -29.1% | -50.4% | -43.8% | 30.4% | 29.4% | 40.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Product / service
$5.31M totalClinical Lab$3.18M · 59.9%
Contract Manufacturing$1.07M · 20.1%
Over The Counte$1.05M · 19.8%
Physicians Office$11.0K · 0.2%
Geographic
$5.31M totalAsia$1.72M · 32.3%
North America$1.66M · 31.2%
Europe$1.30M · 24.4%
Middle East$630.0K · 11.9%
South America$8.0K · 0.2%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing BIOMERICA INC against the 5 most active filers in the same SIC group.